Denali Therapeutics Inc. Sells PRV for $195M

What Happened
Denali Therapeutics announced on July 27, 2026 that it completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to a large pharmaceutical company, receiving gross proceeds of $195.0 million at closing. The company had received the PRV when AVLAYAH™ (tividenofusp alfa) was approved by the U.S. FDA in March 2026 for the treatment of Hunter syndrome (mucopolysaccharidosis type II, MPS II). The sale was completed under an asset purchase agreement dated June 12, 2026; the full PRV Transfer Agreement will be filed as an exhibit to a subsequent SEC filing.

Key Details

• Sale closed on July 27, 2026; gross proceeds to Denali: $195.0 million.
• PRV was issued following FDA approval of AVLAYAH (tividenofusp alfa) in March 2026 for Hunter syndrome (MPS II).
• Transaction governed by a PRV Transfer Agreement dated June 12, 2026; buyer described as a “large pharmaceutical company” (unnamed).
• Denali disclosed the completion in an SEC Form 8-K; the purchase agreement will be filed as an exhibit later.

Why It Matters
This transaction converts a one-time regulatory asset (the PRV) into immediate cash, strengthening Denali’s liquidity by $195M. For investors, that cash inflow can meaningfully impact the company’s near-term funding flexibility—supporting R&D, operations, or balance-sheet needs—without reflecting recurring product revenue. The filing does not state how Denali will use the proceeds or the accounting treatment; the full transfer agreement will be available in a subsequent SEC exhibit for more detail.